Reviva Pharmaceuticals Holdings, Inc. to Participate at the Maxim Virtual Growth Conference

Mar 22, 2022 | Press Releases

CUPERTINO, Calif., March 22, 2022 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...

Reviva Pharmaceuticals Holdings, Inc. to Present at Upcoming Virtual Investor Conferences

Mar 18, 2022 | Press Releases

– 5th Annual Neuroscience Innovation Forum – – BIO-Europe Spring® 2022 – CUPERTINO, Calif., March 18, 2022 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage...

Reviva Pharmaceuticals Holdings, Inc. Reports Full Year 2021 Financial Results and Recent Business Highlights

Mar 15, 2022 | Press Releases

– Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia anticipated in mid-2023 – $29.7 Million in Cash as of December 31, 2021 – CUPERTINO, Calif., March 15, 2022 — Reviva Pharmaceuticals Holdings,...

Reviva Pharmaceuticals Announces First Patients Dosed in Pivotal Phase 3 Study and Long-Term Safety Trial Evaluating Brilaroxazine for the Treatment of Schizophrenia

Feb 1, 2022 | Press Releases

– RECOVER is a Phase 3, randomized, double-blind study with registrational intent – – Reviva anticipates expanding the clinical development of brilaroxazine into other neuropsychiatric indications – CUPERTINO, Calif., Feb. 01, 2022 —...

Reviva Pharmaceuticals Holdings, Inc. Receives FDA May Proceed Letter for Pivotal Phase 3 Clinical Trial and Long-Term Safety Trial Evaluating Brilaroxazine For The Treatment of Schizophrenia

Jan 10, 2022 | Press Releases

– Brilaroxazine is a novel serotonin and dopamine receptor modulator currently being developed for diseases with dysfunctional serotonin signaling including neuropsychiatric and pulmonary indications – – Initiation of both Phase 3 trials is expected...